CCA
IOVA icon

Checchi Capital Advisers’s Iovance Biotherapeutics IOVA Stock Holding History

Checchi Capital Advisers’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-8,000
Closed -$208K – 534
2021
Q2 		$208K Buy
+8,000
New +$208K 0.02% 495

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Checchi Capital Advisers's IOVA Position: Q3 2021 in Review

Checchi Capital Advisers sold out of Iovance Biotherapeutics (IOVA) in Q3 2021, closing a stake of 8,000 shares — an estimated $208K sold.

Checchi Capital Advisers first reported a position in IOVA in Q2 2021 and held it in 1 quarter. The position peaked at $208K in Q2 2021. 243 funds tracked by Wall St. Rank hold IOVA as of Q3 2021.

  • Checchi Capital Advisers reported no remaining Iovance Biotherapeutics position as of Q3 2021 after selling out during the quarter.
  • Checchi Capital Advisers sold 8,000 Iovance Biotherapeutics shares in Q3 2021, an estimated $208K.
  • Checchi Capital Advisers first reported a position in Iovance Biotherapeutics in Q2 2021 and held it in 1 quarter.
  • Checchi Capital Advisers's Iovance Biotherapeutics position peaked at $208K in Q2 2021.
  • 243 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q3 2021.

Based on Checchi Capital Advisers's 13F filing for Q3 2021, filed 9 Nov 2021.